Clinical Trial Update: Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical trial evaluated the combination of metformin with docetaxel in patients with metastatic hormone-refractory prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• metformin (metformin)

Snippet

Sponsor: Centre Antoine Lacassagne | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED